| Object To assess the role of 68Ga-PSMA-11 PET/CT on the diagnosis of CRPC and the pathological characters of treatment-na?ve prostate cancer(PCa)and castrate-resistant prostate cancer(CRPC).Method Twenty-six consecutive patients with treatment-na?ve PCa,23 with CRPC and 3 stable PCa were enrolled,with the age are 53-91(72±9)years oldo The Gleason Score are 6-9,the prostate special antigen(PSA)are 0.01-12356.00ng/mL.68Ga-PSMA-11 PET/CT and magnetic resonance imaging(MRI)were performed for the evaluation of primary prostatic lesions,and bone scans were used for evaluation bone metastasis.68Ga-PSMA-11 PET/CT was performed in all patients at 1h post-injection.Final diagnosis was based on histopathology and imaging follow-up.Patient based analysis and lesion based analysis was performed.Result 68Ga-PSMA-11 PET/CT showed moderate physiologic radiouptake in salivary glands and small intestine,the predominant radiouptake was cleared in kidney.Firty nine patients(26 treatment-na?ve PCa,23 CRPC)showed PSMA-avid lesions on 68Ga-PSMA-11 images,while the 3 patients with stable mCRPC after chemotherapy were negative for PSMA.The sensitivity,specificity and accuracy of 68Ga-PSMA-11 imaging were 98%,100%and 98.08%.All the 26 treatment-na?ve PCa have avid uptake in the primary lesions of prostate.The maximum standardized uptake value(SUVmax)of prostatic lesions was 17.90±10.01 and 14.02±12.45 in treatment-na?ve PCa and mCRPC,respectively.68Ga-PSMA-11 revealed 121metastatic lymph nodes in 19 patients;the SUVmax was 17.34±9.77 and 7.60±5.34 in treatment-na?ve PCa and mCRPC,respectively.Moreover,68Ga-PSMA-11 PET/CT detect bone metastasis in 38 patients(73.08%).68Ga-PSMA-11 PET/CT detect 5 patients with liver metastasis and 4 patients with metastasis.immunohistochemistry accord with the 68Ga-PSMA-11 PET/CT images.Conclusion 68Ga-PSMA-11 PET/CT exhibits potential for staging and risk stratification in na?ve PCa,as well as improved sensitivity for detection of lymph node and remote metastasis. |
PDF Full Text Request